Repository logo
 
Publication

Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal

2023-03Journal article Open access
Simple item page
dc.contributor.authorKislaya, Irina
dc.contributor.authorCasaca, Pedro
dc.contributor.authorBorges, Vítor
dc.contributor.authorSousa, Carlos
dc.contributor.authorFerreira, Bibiana I.
dc.contributor.authorFonte, Ana
dc.contributor.authorFernandes, Eugénia
dc.contributor.authorDias, Carlos Matias
dc.contributor.authorDuarte, Sílvia
dc.contributor.authorAlmeida, José Pedro
dc.contributor.authorGrenho, Inês
dc.contributor.authorCoelho, Luís
dc.contributor.authorFerreira, Rita
dc.contributor.authorFerreira, Patrícia Pita
dc.contributor.authorBorges, Cláudia Medeiros
dc.contributor.authorIsidro, Joana
dc.contributor.authorPinto, Miguel
dc.contributor.authorMenezes, Luís
dc.contributor.authorSobral, Daniel
dc.contributor.authorNunes, Alexandra
dc.contributor.authorSantos, Daniela
dc.contributor.authorGonçalves, António Maia
dc.contributor.authorVieira, Luís
dc.contributor.authorGomes, João Paulo
dc.contributor.authorLeite, Pedro Pinto
dc.contributor.authorNunes, Baltazar
dc.contributor.authorMachado, Ausenda
dc.contributor.authorPeralta-Santos, André
dc.date.accessioned2024-01-22T16:15:30Z
dc.date.available2024-01-22T16:15:30Z
dc.date.issued2023-03
dc.descriptionAuthor affiliations: Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado).
dc.description.abstractWe estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April-June 2022, we implemented a case-case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case-case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93-1.23]) or booster (aOR 0.96 [95% CI 0.84-1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%-90%] vs. VE 93% [95% CI 86%-97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.pt_PT
dc.description.sponsorshipThe acquisition of sequencing equipment and reagents used in this study by the Instituto Nacional de Saúde Doutor Ricardo Jorge was partially funded by the HERA project (grant no. 2021/PHF/23776) supported by the European Commission through the European Centre for Disease Control, and also partially funded by the GenomePT project (grant no. POCI-01-0145-FEDER-022184), supported by COMPETE 2020–Operational Programme for Competitiveness and Internationalisation, Lisboa Portugal Regional Operational Programme, Algarve Portugal Regional Operational, under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund, and by the Portuguese Science and Technology Foundation. Algarve Biomedical Center Laboratory received public funding through the Project ALG-D2-2021-06 Variants Screen in Southern Portugal– Monitoring Variants of Concern in Southern Portugal and the Portuguese Science and Technology Foundation national support through the Comprehensive Health Research Center (grant no. UIDP/04923/2020)pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEmerg Infect Dis. 2023 Mar;29(3):569-575. doi: 10.3201/eid2903.221367. Epub 2023 Feb 3pt_PT
dc.identifier.doi10.3201/eid2903.221367pt_PT
dc.identifier.issn1080-6040
dc.identifier.urihttp://hdl.handle.net/10400.18/8950
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherCenters for Disease Control and Preventionpt_PT
dc.relationNational Facility for genome sequencing and analysis
dc.relationComprehensive Health Research Center - Research, Education, Training and Innovation in Clinical research and Public Health
dc.relation.publisherversionhttps://wwwnc.cdc.gov/eid/article/29/3/22-1367_articlept_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectBA.2pt_PT
dc.subjectBA.5pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectOmicronpt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectCoronavirus Diseasept_PT
dc.subjectDeathpt_PT
dc.subjectHospitalizationpt_PT
dc.subjectPostinfection Vaccine Effectivenesspt_PT
dc.subjectRespiratory Infectionspt_PT
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2pt_PT
dc.subjectVaccine-preventable Diseasespt_PT
dc.subjectVirusespt_PT
dc.subjectPortugalpt_PT
dc.subjectInfecções Respiratóriaspt_PT
dc.subjectDoenças Evitáveis pela Vacinaçãopt_PT
dc.subjectDeterminantes da Saúde e da Doençapt_PT
dc.titleComparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugalpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleNational Facility for genome sequencing and analysis
oaire.awardTitleComprehensive Health Research Center - Research, Education, Training and Innovation in Clinical research and Public Health
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/9444 - RNIIIE/PINFRA%2F22184%2F2016/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04923%2F2020/PT
oaire.citation.endPage575pt_PT
oaire.citation.issue3pt_PT
oaire.citation.startPage569pt_PT
oaire.citation.titleEmerging Infectious Diseasespt_PT
oaire.citation.volume29pt_PT
oaire.fundingStream9444 - RNIIIE
oaire.fundingStream6817 - DCRRNI ID
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.embargofctAcesso de acordo com a política editorial da revista.pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isProjectOfPublication3b8a803c-37e5-4354-93f5-6410d7fb2af7
relation.isProjectOfPublicationfca49be7-f346-4551-94a8-e107ebc974f6
relation.isProjectOfPublication.latestForDiscovery3b8a803c-37e5-4354-93f5-6410d7fb2af7

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2023 - Kislaya et al 2023 (EID).pdf
Size:
389.7 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DDI - Artigos em revistas internacionais
DEP - Artigos em revistas internacionais
DGH - Artigos em revistas internacionais